biotech
<a href="https://www.fiercebiotech.com/biotech/ox40-drug-inhibrx-mooted-ma-target-tops-keytruda-early-look-midphase-data" hreflang="en">Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data </a>
FierceBiotech
May 11, 2026 · 22s listen
Listen · FierceBiotech
<a href="https://www.fiercebiotech.com/biotech/ox40-drug-inhibrx-mooted-ma-target-tops-keytruda-early-look-midphase-data" hreflang="en">Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data </a>
0:00-0:22
Live · Kokoro-82M
Audio pre-rendered by Storyflo · cached + delivered from the edge
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of Merck & Co.
Share
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to FierceBiotech.
Heard via Storyflo
Get audio versions of every article you read.
Pick what matters — your audio curator gets you into your daily flo.